News roundup

Pentosan polysulphate prolongs survival in CJD, study indicates

London Owen Dyer

An experimental treatment for Creutzfeldt-Jakob disease (CJD) may prolong life but does not seem to halt progressive deterioration of the brain, a study of seven British patients who took the drug has found.

Pentosan polysulphate, widely prescribed in pill form around the world for urological conditions, is infused directly into the brain of patients with CJD.

Ian Bone, a Glasgow neurologist, did the study on behalf of the Medical Research Council. Of the seven patients, three had variant CJD (vCJD, contracted from bovine spongiform encephalopathy); two had iatrogenic prion disease from growth hormone; and two had the hereditary form of CJD. All were aged under 35. Three of the seven died before the study’s end.

Professor Bone told the BMJ that his findings indicated, but did not prove, that the drug prolongs survival. “The average survival in vCJD is generally believed to be about 13 months. All . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article

Family finds hospital willing to give experimental CJD treatment

Owen Dyer
BMJ 2003 326: 8. [Extract] [Full Text] [PDF]